J
Julie A. Anderson
Researcher at GlaxoSmithKline
Publications - 59
Citations - 11531
Julie A. Anderson is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: COPD & Fluticasone propionate. The author has an hindex of 29, co-authored 58 publications receiving 10793 citations. Previous affiliations of Julie A. Anderson include RAND Corporation.
Papers
More filters
Journal ArticleDOI
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Julie A. Anderson,Bartolome R. Celli,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Julie C. Yates,Jørgen Vestbo +6 more
TL;DR: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance, and there were significant benefits in all other outcomes among these patients.
Journal ArticleDOI
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial
TL;DR: Improvements in clinical outcomes support the use of this treatment in patients with moderate to severe chronic obstructive pulmonary disease as patients on fluticasone propionate had fewer exacerbations and a slower decline in health status.
Journal ArticleDOI
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Peter M.A. Calverley,Romain Pauwels,Jørgen Vestbo,Paul W. Jones,Neil B. Pride,Amund Gulsvik,Julie A. Anderson,Claire Maden +7 more
TL;DR: In this article, a randomized, double-blind, parallel-group, placebo-controlled study with inhaled long-acting β 2 agonists and corticosteroid combination treatment produces better control of symptoms and lung function, with no greater risk of side-effects than that with use of either component alone.
Journal ArticleDOI
Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease Results from the TORCH Study
Bartolome R. Celli,Nicola E. Thomas,Julie A. Anderson,Gary T. Ferguson,Christine Jenkins,Paul W. Jones,Jørgen Vestbo,Katharine Knobil,Julie C. Yates,Peter M.A. Calverley +9 more
TL;DR: Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression.
Journal ArticleDOI
Ascertainment of Cause-Specific Mortality in COPD -- Operations of the TORCH Clinical Endpoint Committee
TL;DR: A CEC can provide standardised, reliable and informative adjudication of COPD mortality that provides information which frequently differs from data collected from assessment by site investigators.